CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 789 enrolled
Drug / intervention
Peginterferon alfa-2b (SCH 54031) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00705666
NCT00705666N/ACompleted
CompareCT.gov

Real Situation Observational Study of VIRAFERONPEG® in Patients With Chronic Hepatitis C

Merck Sharp & Dohme LLC·observational·Posted Jun 26, 2008·Updated Oct 2, 2015

In Brief

An observational study evaluating Peginterferon alfa-2b (SCH 54031) and Ribavirin (SCH 18908) for Hepatitis C, Chronic and Hepacivirus. Completed, enrolled 789 participants.

Detailed Summary

In February 2002, a French Consensus Conference on the management of patients with chronic hepatitis C in France was organized. The jury issued several recommendations on pegylated alpha interferon/ribavirin treatment strategy. Three years after these recommendations, it is of interest to understand the evolution of hepatitis C management in France in real clinical practice. This observational study will permit the identification of patients who are treated and will provide information on the use of PegIntron/ Ribavirin.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic, Hepacivirus
Countries--
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 26, 2008
Enrollment StartFeb 1, 2006
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 18.0 years ago

Interventions

Peginterferon alfa-2b (SCH 54031)biological

Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.

Ribavirin (SCH 18908)drug

Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.